Free Trial

Madrigal Pharmaceuticals (MDGL) Earnings Date, Estimates & Call Transcripts

Madrigal Pharmaceuticals logo
$539.73 +37.26 (+7.42%)
Closing price 04:00 PM Eastern
Extended Trading
$534.00 -5.73 (-1.06%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals Earnings Summary

Madrigal Pharmaceuticals announced Q1 2026 earnings on May 6, 2026, reporting an EPS of -$3.25, which beat the consensus estimate of -$4.23 by $0.98. Quarterly revenue rose 126.8% year-over-year to $311.34 million, above analysts' expectations of $301.05 million. With a trailing EPS of -$12.87, Madrigal Pharmaceuticals' earnings are expected to grow next year, from ($5.49) to $12.45 per share.

Latest Q1
Earnings Date
May. 6Estimated
Consensus EPS
(May. 6)
-$4.23
Actual EPS
(May. 6)
-$3.25 Beat By $0.98
Actual Revenue
(May. 6)
$311.34M

Q1 2026 Earnings Resources

Get Madrigal Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

MDGL Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MDGL Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Madrigal Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$0.32$3.02$1.35
Q2 20262$1.66$4.40$3.03
Q3 20262$2.24$4.84$3.54
Q4 20262$3.27$5.18$4.23

Madrigal Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026-$4.2296-$3.25+$0.9796-$3.25$301.05M$311.34M
2/19/2026Q4 2025$0.04-$2.57 -$2.61-$2.57$310.36M$321.08M
11/4/2025Q3 2025-$2.01-$5.08 -$3.07-$5.08$244.33M-
8/5/2025Q2 2025-$3.48-$1.90+$1.58-$1.90$158.94M$212.80M
5/1/2025Q1 2025-$3.62-$3.32+$0.30-$3.32$112.79M$137.25M
2/26/2025Q4 2024-$4.32-$2.71+$1.61-$2.71$97.81M$103.32M
10/31/2024Q3 2024-$6.94-$4.92+$2.02-$4.92$34.60M$62.18M
8/7/2024Q2 2024-$7.55-$7.10+$0.45-$7.10$4.25M$14.64M
5/7/2024Q1 2024-$6.06-$7.38 -$1.32-$7.38--

Data powered by Fiscal.ai.

Madrigal Pharmaceuticals Earnings - Frequently Asked Questions

Madrigal Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 6th, 2026 based off last year's report dates. Learn more on MDGL's earnings history.

In the previous quarter, Madrigal Pharmaceuticals (NASDAQ:MDGL) reported ($3.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($4.23) by $0.98. Learn more on analysts' earnings estimate vs. MDGL's actual earnings.

The conference call for Madrigal Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Madrigal Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a recorded annual revenue of $958.40 million.

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a recorded net income of -$288.28 million. MDGL has generated -$12.87 earnings per share over the last four quarters.

Madrigal Pharmaceuticals' earnings are expected to grow from ($5.49) per share to $12.45 per share in the next year.


This page (NASDAQ:MDGL) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners